Immunotherapy involves the use of many active agents such as cells, cytokines or vaccines (among others). These agents are used to induce, enhance or suppress the function of the immune system.
Daratumumab is a drug used for the treatment of multiple myeloma. It is for use in people who have multiple myeloma who have already received at least one prior therapy. It is given as an injection into a vein through an IV.
Ipilimumab is a cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat melanoma. It is also being studied in the treatment of other types of cancers, including multiple myeloma.
Normally, your immune system helps defend against internal threats, such as cancer, using specialized immune cells called T cells. Some types of cancer cells present a protein called PD-L1, which interacts with the PD-1 receptor on your T cells. This can deactivate your T cells and prevent them from recognizing and attacking the cancer. Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.
A T cell or T lymphocyte is a type of lymphocyte (a subtype of white blood cell) that plays a central role in cell-mediated immunity.
GSK2857916 is an antibody-drug conjugate (ADC) with anti-BCMA antibody that binds to BCMA on tumor cell surfaces causing cell cycle arrest and inducing antibody-dependent cellular cytotoxicity (ADCC).
SEA-BCMA is a new antibody targeting the BCMA protein and being tested in multiple myeloma.
Atezolizumab is a new drug being tested in myeloma. It targets a protein called PDL-1 which is normally involved in dampening the immune response. This increases the activity of the immune system to recognize and destroy myeloma cells.
Cetuximab is a cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat colorectal cancer and squamous cell carcinoma of the head and neck. It is also being studied in the treatment of other types of cancers, including multiple myeloma.
SGN-CD48A is a novel humanized anti-cd48 antibody-drug conjugate being tested for the treatment of multiple myeloma.
PVX-410 is a vaccine that can stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens.
bb2121 is a new treatment being investigated in myeloma that belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This involves T-cells being taken from the patient and being changed to find myeloma cells more easily. When it finds myeloma cells, bb2121 removes and destroys them.
BION-1301 is a humanized antibody that blocks A PRoliferation-Inducing Ligand (APRIL) from binding to its receptors, using Aduro’s B-select monoclonal antibody platform. In preclinical studies, BION-1301 eliminated malignant cells and reduced resistance to therapy in models of multiple myeloma.
Elotuzumab is a drug used for the treatment of multiple myeloma. It is for use in patients who have received one to three prior medications and is intended to be used in combination with lenalidomide and dexamethasone. It is given as an injection into a vein through an IV.
Natural Killer Cells can work in cancer treatment by being modified to recognize and attack tumor cells in the body. Natural Killer Cells are already found in the body, and are unique because they are able to recognize and attack cells without being acted upon by an antigen (immunization).
Denosumab is a humanized monoclonal antibody that binds to RANKL and blocks the interaction of RANKL with RANK, resulting in inhibition of bone destroying cells and a decrease in bone breakdown.
TAK-079 is a fully human, non-agonistic, IgG1 cell-depleting monoclonal antibody that binds human CD38 with high affinity.
SAR650984 is a humanized IgG1 monoclonal antibody that binds to CD38+ cells, triggerring antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and tumor programmed cell death.
One way your immune system controls the activity of T cells is through the PD-1 pathway. Some cancer cells can hide from the T cells attack by taking control of the PD-1 pathway. This stops T cells from attacking cancer cells. Pembrolizumab works by blocking the PD-1 pathway. The Keynote Clinical Trials are studying whether pembrolizumab can help treat patients with various types of cancer.One way your immune system controls the activity of T cells is through the PD-1 pathway. Some cancer cells can hide from the T cells attack by taking control of the PD-1 pathway. This stops T cells from attacking cancer cells. Pembrolizumab works by blocking the PD-1 pathway. The Keynote Clinical Trials are studying whether pembrolizumab can help treat patients with various types of cancer.
Cancer treatment with the Measles Virus can work by modifying the virus to only infect cancer cells. Once injected into the body, the virus then can seek out and kill the cancer cells.
TTI-621 is a novel checkpoint inhibitor of the innate immune system, in relapsed or refractory hematologic malignancies.
An antibody-drug conjugate (ADC) composed of a proprietary monoclonal antibody against an unnamed tumor-associated antigen (TAA) linked to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon intravenous administration, the monoclonal antibody moiety of MEDI7247 targets and binds to the TAA expressed on tumor cells. Upon binding and internalization, the cytotoxic agent is released and kills the TAA-expressing cancer cells, through an as of yet unknown mechanism of action.
Lintuzumab AC 225 is an Antibody Radio-Conjugate (ARC) comprised of the anti-CD33 monoclonal antibody lintuzumab labeled with the radioisotope actinium-225.
JNJ-68284528 (LCAR-B38M) is an autologous CAR-T therapy that targets B-Cell Maturation Antigen (BCMA), a molecule expressed on the surface of mature B lymphocytes and malignant plasma cells. The investigational therapy expresses an identical CAR protein as Legend's LCAR-B38M CAR-T product, which was evaluated in a first-in-human clinical study (Legend-2) conducted in multiple sites by Legend Biotech in China.
GBR 1342 is a humanized, bispecific monoclonal antibody (bsAb) that is designed to activate the patient's immune system by redirecting immune cells towards tumor tissue, which may lead to targeted destruction of tumors.
bb21217 is a new treatment being investigated in myeloma that belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This involves T-cells being taken from the patient and being changed to find myeloma cells more easily.
BFCR4350A is a bispecific T-cell engager (BiTE) antibody. It targets both the the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and as well as the CD3 antigen found on T lymphocytes.
JNJ-64007957 is a bispecific antibody that targets BCMA, which is expressed in mature B lymphocytes, and CD3, which is expressed on T-cells.
AMG 701 is a bispecific antibody that targets both CD-3 and BCMA that is being tested in multiple myeloma.
SurVaxM is a first-of-its-kind, patented peptide mimic immunotherapeutic vaccine (immunotherapy) that targets survivin, a cell-survival protein present in 95 percent of glioblastomas and many other cancers. It is engineered to recognize survivin-expressing cancer cells as foreign and stimulate patients’ own immune response to control tumor growth and recurrence.
Prevnar 13 is a vaccine containing 13 different strains of the bacterium Streptococcus pneumoniae for the prevention of pneumococcal disease in immunocompromised patients with cancer.
AMG-224 is a new drug being tested in myeloma called an antibody-drug conjugate comprised of anti-BCMA–MCC–DM1. It consists of a chemotherapy drug combined with a monoclonal antibody which helps to deliver the drug to myeloma cells.
AMG 420 is made using Amgen’s proprietary BiTE or “bispecific T-cell engager” technology. AMG 420 consists of two proteins fused together, each designed to interact with a specific target — in this case, BCMA and CD3, a protein found on the surface of T-cells.
AMG 424 is a novel, humanized, bispecific T cell-recruiting anti-CD3/CD38 antibody.
CAR2 Anti-CD38 A2 CAR-T Cells has the key advantage of selectively killing high expressing CD38 positive cells, which are mostly cancer cells and thus, may limit on-target/off-tumor toxicity. CAR2 Anti-CD38 A2 CAR-T Cells are being evaluated in multiple myeloma (MM) and has successfully demonstrated strong preclinical anti-tumor activity in animal models.
CC-93269 is a T-cell bi-specific antibody targeting both BCMA and CD3 in patients with multiple myeloma.
Cemiplimab REGN2810 is a fully human anti-PD-1 monoclonal antibody.
Descartes-08 is a cell therapy wherein T-cells are modified to attack myeloma cells. To modify the cells, new instructions (called RNA) are inserted into the T-cells.
Durvalumab is an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1). PD-L1 can be expressed by tumours to evade detection by the immune system through binding to PD-1 on cytotoxic T lymphocytes. Durvalumab blocks the PD-L1 interaction with PD-1, countering the tumour's immune-evading tactics. Durvalumab is being developed, alongside other immunotherapies, to strengthen the patient's immune system and attack the cancer.
FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46.
JCARH125 is a CAR T-cell product that targets B-cell maturation antigen (BCMA).
JNJ-64407564 is a bispecific monoclonal antibody binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells.
MEDI2228 is a novel antibody drug conjugate that targets BCMA.
PF-06863135 is a B-cell Maturation Antigen (Bcma)-cd3 bispecific antibody being tested in multiple myeloma.
Reolysin is a serotype 3 Dearing strain (T3D) of reovirus that replicates and induces programmed tumor cell death in RAS-activated tumor cells.
SGN-CD352A is an antibody drug conjugate that can work by targeting specific areas of the cancer cell, attacking it, and inducing rapid cell death.
SRF231 is a fully human monoclonal antibody that targets and inhibits the activity of the CD47 protein that is highly expressed in cancer cells. CD47 works as a signal that prevents cancer cells from being recognized by the immune system and macrophages. By blocking CD47 signaling, SRF231 may allow macrophages to recognize and destroy cancer cells.
STRO-001 is an antibody drug conjugate targeting CD74, a cell surface protein associated with B-cell malignancies, including non-Hodgkin lymphoma and multiple myeloma.
Create your account today and get matched to myeloma treatments and trials around the US.
Weekdays 9am - 5pm EST